An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Completed · Not applicable

Conditions studied: Psoriasis, Atopic Dermatitis

In brief

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo TM) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self- processing) to optimally improve a participant's health.

Key facts

Study ID

NCT06275659

Run by

Click Therapeutics, Inc.

People needed

120

Starts

2023-12-04

Expected to finish

2024-02-23

Last updated by the study team

2025-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fluent in written and spoken English, confirmed by ability to read, understand and sign the informed consent form (ICF).
• Lives in the United States.
• Aged 18 years or older.
• Itch NRS ≥ 4 during screening.
• Meets indication-specific inclusion criteria (see Appendix 1), as reported by the study participant with adequate clinical documentation. (Documentation to be provided to the study team upon request.)
• Has an active email address and is willing and able to receive and respond to email messages.
• Has access to an internet connection during the study duration.
• Willing and able to comply with the study protocol and assessments.
• Is the sole user of an iPhone with an iPhone operating system (OS) 14 or later or a smartphone with an Android OS 10 or later for the duration of the study.
• Is willing and able to receive Short Message Service (SMS) text messages and notifications on their smartphone.

You may not qualify if…

• Pregnant or planning to become pregnant.
• Visual, dexterity or cognitive deficit so severe that it precludes the use of an App-based, reaction-time-based activity per investigator judgment.
• Severe psychiatric disorder involving a history of psychosis (e.g., schizophrenia, bipolar disorder or severe personality disorders).
• Psychiatric hospitalization in the past 6 months.
• Participation in any research study (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the past 3 months.
• Initiation or change in primary-disease-specific medication within 30 days prior to entering the study.
• Self-reported substance-use disorder within the past 1 year.
• Currently experiencing a skin infection.
• Planning the introduction of new therapies (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the 7-week study period.
• Anticipating a change in current pharmacological or psychotherapy treatment regimen during the 7-week study period.

Where it is running

• Click Therapeutics — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.